標(biāo)題：利瑞魯單抗，Lirilumab，CAS:1000676-41-4， AntibodySystem Laboratories

貨號：DHE43401

產(chǎn)品鏈接：http://www.atagenix.com/product_detail-75537.html

別名：BMS-986015, IPH2102, CAS: 1000676-41-4

簡介：

Lirilumab (IPH2102) 是一種 anti-KIR 單克隆抗體，其具有抗腫瘤活性。Lirilumab 可用于白血病、頭頸部鱗狀細胞癌 (SCCHN) 的研究。

形態(tài)：Liquid

保存：0.01M PBS, pH 7.4.

濃度：1 mg/ml

純度：>95%

克隆性：Monoclonal

亞型：IgG4-kappa

應(yīng)用：Research Grade Biosimilar

參考文獻：

Neoadjuvant and Adjuvant Nivolumab and Lirilumab in Patients with Recurrent, Resectable Squamous Cell Carcinoma of the Head and Neck. PMID: 34667025
Lirilumab and Avelumab Enhance Anti-HPV+ Cervical Cancer Activity of Natural Killer Cells via Vav1-Dependent NF-κB Disinhibition. PMID: 35174079
A Pilot Trial of Lirilumab With or Without Azacitidine for Patients With Myelodysplastic Syndrome. PMID: 30001986
A phase 1 study of lirilumab (antibody against killer immunoglobulin-like receptor antibody KIR2D; IPH2102) in patients with solid tumors and hematologic malignancies. PMID: 29707140
High affinity anti-TIM-3 and anti-KIR monoclonal antibodies cloned from healthy human individuals. PMID: 28723950
Anti-KIR antibody enhancement of anti-lymphoma activity of natural killer cells as monotherapy and in combination with anti-CD20 antibodies. PMID: 24326534
How to outsmart NK cell tolerance. PMID: 26405590
A phase 1b study of dual PD-1 and CTLA-4 or KIR blockade in patients with relapsed/refractory lymphoid malignancies. PMID: 32601377
Immunogenomic correlates of response to cetuximab monotherapy in head and neck squamous cell carcinoma. PMID: 30828910
Trial Watch: Immunostimulatory monoclonal antibodies in cancer therapy. PMID: 24701370